Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment
Summary
USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.
What changed
USPTO published patent application US20260097013A1, a pre-grant publication covering compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application includes formulations combining ABDNAZ with autologous whole blood for rapid IV infusion without significant infusion-site pain.
Affected parties, including pharmaceutical companies, drug manufacturers, and researchers developing cancer therapeutics, should monitor this application for potential freedom-to-operate implications, licensing opportunities, or competitive intelligence purposes. Patent applications are informational publications and do not grant enforceable rights until an issued patent is obtained following examination.
What to do next
- Monitor for USPTO patent application status updates
- Review patent claims for potential licensing opportunities
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE
Application US20260097013A1 Kind: A1 Apr 09, 2026
Inventors
Bryan T. ORONSKY, Jan SCICINSKI, Scott CAROEN
Abstract
The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl) ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.
CPC Classifications
A61K 31/397 A61K 9/0019 A61K 31/194 A61K 31/727 A61K 35/14 A61K 47/10 A61K 47/18 A61P 35/00 A61P 35/02 A61K 9/08 A61K 47/46
Filing Date
2025-06-11
Application No.
19235544
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.